Home Enanta Announces SVR12 Results Of 95% From AbbVie's GIFT-1 Study In Non-Cirrhotic, Japanese Patients With Genotype 1b Hepatitis C Virus1
 

Keywords :   


Enanta Announces SVR12 Results Of 95% From AbbVie's GIFT-1 Study In Non-Cirrhotic, Japanese Patients With Genotype 1b Hepatitis C Virus1

2015-06-03 06:35:57| drugdiscoveryonline Home Page

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced recently that new data from AbbVie’s phase 3 GIFT-I study, its investigational, all-oral, interferon (IFN)- and ribavirin (RBV)-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir, was presented at the Annual Meeting of the Japan Society of Hepatology in Kumamoto, Japan

Tags: c results study japanese

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
28.11
28.11MF MFsoftbord twintown
28.11T800
28.11162
28.112 117
28.112CD+DVD
28.114
28.11Nike Iowa 90s
More »